Frontiers in Oncology
Circulating tumor DNA in neoadjuvant therapy for solid tumors
Circulating tumor DNA (ctDNA), a core component of liquid biopsy, demonstrates significant potential in the field of neoadjuvant therapy for solid tumors. This review systematically examines the role of ctDNA across the pre-, intra-, and post-neoadjuvant treatment phases, with a focus on its value in predicting therapeutic efficacy, assessing early treatment response, detecting minimal residual disease (MRD), and monitoring for recurrence. By synthesizing the latest clinical research data and advancements in molecu …